Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
2,653 questions in 194 reviews · Gynaecology and Fertility
current versionsNo studies 531 · 20%Ungraded 76 · 2.9%Very low 826 · 31.1%Low 855 · 32.2%Moderate 341 · 12.9%High 24 · 0.9%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Conical blunt‐tipped trocar vs cutting trocar Postoperative pain5 · people undergoing laparoscopy Trocar types in laparoscopy (2015) · Cochrane | no estimate extracted | 1 study · 42 participants | Very low |
Radially expanding trocar vs conical blunt‐tipped trocar Visceral injury · people undergoing laparoscopy Trocar types in laparoscopy (2015) · Cochrane | no estimate extracted | 1 study · 28 participants | Very low |
Radially expanding trocar vs conical blunt‐tipped trocar Vascular injury · people undergoing laparoscopy Trocar types in laparoscopy (2015) · Cochrane | no estimate extracted | 1 study · 28 participants | Very low |
Radially expanding trocar vs conical blunt‐tipped trocar Trocar site herniation · people undergoing laparoscopy Trocar types in laparoscopy (2015) · Cochrane | no estimate extracted | 1 study · 28 participants | Very low |
Single‐bladed trocar vs pyramidal‐bladed trocar Visceral injury · people undergoing laparoscopy Trocar types in laparoscopy (2015) · Cochrane | no estimate extracted | 1 study · 28 participants | Very low |
Single‐bladed trocar vs pyramidal‐bladed trocar Vascular injury · people undergoing laparoscopy Trocar types in laparoscopy (2015) · Cochrane | no estimate extracted | 1 study · 28 participants | Very low |
Single‐bladed trocar vs pyramidal‐bladed trocar Trocar site herniation · people undergoing laparoscopy Trocar types in laparoscopy (2015) · Cochrane | no estimate extracted | 1 study · 28 participants | Very low |
Radially expanding trocars vs cutting trocars Vascular injury · people undergoing laparoscopy Trocar types in laparoscopy (2015) · Cochrane | OR 0.14 [0, 7.16] | 4 studies · 473 participants | Very low |
Radially expanding trocars vs cutting trocars Trocar site herniation · people undergoing laparoscopy Trocar types in laparoscopy (2015) · Cochrane | no estimate extracted | 4 studies · 463 participants | Very low |
Radially expanding trocars vs cutting trocars Trocar site bleeding · people undergoing laparoscopy Trocar types in laparoscopy (2015) · Cochrane | OR 0.28 [0.14, 0.54] | 5 studies · 553 participants | Very low |
Radially expanding trocars vs cutting trocars Trocar site haematoma5 · people undergoing laparoscopy Trocar types in laparoscopy (2015) · Cochrane | no estimate extracted | 2 studies · 238 participants | Very low |
Radially expanding trocars vs cutting trocars Postoperative pain6 · people undergoing laparoscopy Trocar types in laparoscopy (2015) · Cochrane | no estimate extracted | 4 studies · 306 participants | Ungraded |
Conical blunt‐tipped trocar vs cutting trocar Visceral injury · people undergoing laparoscopy Trocar types in laparoscopy (2015) · Cochrane | no estimate extracted | 1 study · 42 participants | Very low |
Conical blunt‐tipped trocar vs cutting trocar Vascular injury · people undergoing laparoscopy Trocar types in laparoscopy (2015) · Cochrane | no estimate extracted | 1 study · 42 participants | Very low |
Conical blunt‐tipped trocar vs cutting trocar Trocar site bleeding · people undergoing laparoscopy Trocar types in laparoscopy (2015) · Cochrane | OR 0.13 [0.01, 2.12] | 1 study · 30 participants | Very low |
GnRH‐a + medroxyprogesterone acetate vs GnRH‐a ± placebo Quality of life · patients with uterine fibroids Add‐back therapy with GnRH analogues for uterine fibroids (2015) · Cochrane | no estimate extracted | NR | No studies |
GnRH‐a + tibolone vs GnRH‐a ± placebo Uterine bleeding · patients with uterine fibroids Add‐back therapy with GnRH analogues for uterine fibroids (2015) · Cochrane | no estimate extracted | NR | No studies |
GnRH‐a + tibolone vs GnRH‐a ± placebo Severity of vasomotor symptoms (SMD) ‐ · patients with uterine fibroids Add‐back therapy with GnRH analogues for uterine fibroids (2015) · Cochrane | no estimate extracted | 4 studies · 268 participants | Ungraded |
GnRH‐a + tibolone vs GnRH‐a ± placebo Rate of vasomotor symptoms ‐ · patients with uterine fibroids Add‐back therapy with GnRH analogues for uterine fibroids (2015) · Cochrane | RR 0.38 [0.14, 1.02] | 1 study · 20 participants | Low |
GnRH‐a + raloxifene vs GnRH‐a ± placebo Quality of life (SMD) ‐ · patients with uterine fibroids Add‐back therapy with GnRH analogues for uterine fibroids (2015) · Cochrane | no estimate extracted | 1 study · 74 participants | Low |
GnRH‐a + raloxifene vs GnRH‐a ± placebo Bone density (SMD) ‐ · patients with uterine fibroids Add‐back therapy with GnRH analogues for uterine fibroids (2015) · Cochrane | no estimate extracted | 1 study · 91 participants | Low |
GnRH‐a + raloxifene vs GnRH‐a ± placebo Uterine size (cm3) ‐ · patients with uterine fibroids Add‐back therapy with GnRH analogues for uterine fibroids (2015) · Cochrane | no estimate extracted | 1 study · 91 participants | Low |
GnRH‐a + raloxifene vs GnRH‐a ± placebo Uterine bleeding (VAS) ‐ · patients with uterine fibroids Add‐back therapy with GnRH analogues for uterine fibroids (2015) · Cochrane | no estimate extracted | 1 study · 91 participants | Low |
GnRH‐a + raloxifene vs GnRH‐a ± placebo Severity of vasomotor symptoms (no. of hot flushes per day) ‐ · patients with uterine fibroids Add‐back therapy with GnRH analogues for uterine fibroids (2015) · Cochrane | no estimate extracted | 1 study · 91 participants | Low |
GnRH‐a + raloxifene vs GnRH‐a ± placebo Rate of vasomotor symptoms · patients with uterine fibroids Add‐back therapy with GnRH analogues for uterine fibroids (2015) · Cochrane | no estimate extracted | NR | No studies |
GnRH‐a + estriol vs GnRH‐a ± placebo Quality of life · patients with uterine fibroids Add‐back therapy with GnRH analogues for uterine fibroids (2015) · Cochrane | no estimate extracted | NR | No studies |
GnRH‐a + medroxyprogesterone acetate vs GnRH‐a ± placebo Bone density (SMD) ‐ · patients with uterine fibroids Add‐back therapy with GnRH analogues for uterine fibroids (2015) · Cochrane | no estimate extracted | 1 study · 16 participants | Low |
GnRH‐a + estriol vs GnRH‐a ± placebo Bone density (SMD) ‐ · patients with uterine fibroids Add‐back therapy with GnRH analogues for uterine fibroids (2015) · Cochrane | no estimate extracted | 1 study · 12 participants | Low |
GnRH‐a + estriol vs GnRH‐a ± placebo Uterine Size · patients with uterine fibroids Add‐back therapy with GnRH analogues for uterine fibroids (2015) · Cochrane | no estimate extracted | NR | No studies |
GnRH‐a + estriol vs GnRH‐a ± placebo Uterine bleeding · patients with uterine fibroids Add‐back therapy with GnRH analogues for uterine fibroids (2015) · Cochrane | no estimate extracted | NR | No studies |
GnRH‐a + estriol vs GnRH‐a ± placebo Severity of vasomotor symptoms · patients with uterine fibroids Add‐back therapy with GnRH analogues for uterine fibroids (2015) · Cochrane | no estimate extracted | NR | No studies |
GnRH‐a + estriol vs GnRH‐a ± placebo Rate of vasomotor symptoms · patients with uterine fibroids Add‐back therapy with GnRH analogues for uterine fibroids (2015) · Cochrane | no estimate extracted | NR | No studies |
GnRH‐a + ipriflavone vs GnRH‐a ± placebo Quality of life · patients with uterine fibroids Add‐back therapy with GnRH analogues for uterine fibroids (2015) · Cochrane | no estimate extracted | NR | No studies |
GnRH‐a + ipriflavone vs GnRH‐a ± placebo Bone density (SMD) ‐ · patients with uterine fibroids Add‐back therapy with GnRH analogues for uterine fibroids (2015) · Cochrane | no estimate extracted | 1 study · 95 participants | Low |
GnRH‐a + ipriflavone vs GnRH‐a ± placebo Uterine size · patients with uterine fibroids Add‐back therapy with GnRH analogues for uterine fibroids (2015) · Cochrane | no estimate extracted | NR | No studies |
GnRH‐a + ipriflavone vs GnRH‐a ± placebo Uterine bleeding · patients with uterine fibroids Add‐back therapy with GnRH analogues for uterine fibroids (2015) · Cochrane | no estimate extracted | NR | No studies |
GnRH‐a + ipriflavone vs GnRH‐a ± placebo Severity of vasomotor symptoms · patients with uterine fibroids Add‐back therapy with GnRH analogues for uterine fibroids (2015) · Cochrane | no estimate extracted | NR | No studies |
GnRH‐a + medroxyprogesterone acetate vs GnRH‐a ± placebo Uterine size (cm3) ‐ · patients with uterine fibroids Add‐back therapy with GnRH analogues for uterine fibroids (2015) · Cochrane | no estimate extracted | 2 studies · 32 participants | Low |
GnRH‐a + ipriflavone vs GnRH‐a ± placebo Rate of vasomotor symptoms ‐ · patients with uterine fibroids Add‐back therapy with GnRH analogues for uterine fibroids (2015) · Cochrane | RR 0.67 [0.44, 1.02] | 1 study · 95 participants | Low |
GnRH‐a + conjugated estrogens vs GnRH‐a ± placebo Reduction in uterine size · women with uterine fibroids Add‐back therapy with GnRH analogues for uterine fibroids (2015) · Cochrane | no estimate extracted | 1 study · 27 participants | Very low |
GnRH‐a + medroxyprogesterone acetate vs GnRH‐a ± placebo Uterine bleeding · patients with uterine fibroids Add‐back therapy with GnRH analogues for uterine fibroids (2015) · Cochrane | no estimate extracted | NR | No studies |
GnRH‐a + medroxyprogesterone acetate vs GnRH‐a ± placebo Severity of vasomotor symptoms · patients with uterine fibroids Add‐back therapy with GnRH analogues for uterine fibroids (2015) · Cochrane | no estimate extracted | NR | No studies |
GnRH‐a + medroxyprogesterone acetate vs GnRH‐a ± placebo Rate of vasomotor symptoms ‐ · patients with uterine fibroids Add‐back therapy with GnRH analogues for uterine fibroids (2015) · Cochrane | RR 0.13 [0.02, 0.84] | 1 study · 16 participants | Low |
GnRH‐a + tibolone vs GnRH‐a ± placebo Quality of life (SMD) ‐ · patients with uterine fibroids Add‐back therapy with GnRH analogues for uterine fibroids (2015) · Cochrane | no estimate extracted | 1 study · 110 participants | Low |
GnRH‐a + tibolone vs GnRH‐a ± placebo Bone density (SMD) ‐ · patients with uterine fibroids Add‐back therapy with GnRH analogues for uterine fibroids (2015) · Cochrane | no estimate extracted | 3 studies · 160 participants | Moderate |
GnRH‐a + tibolone vs GnRH‐a ± placebo Uterine size (cm3) ‐ · patients with uterine fibroids Add‐back therapy with GnRH analogues for uterine fibroids (2015) · Cochrane | no estimate extracted | 6 studies · 365 participants | Moderate |
DHEA vs control (placebo or no treatment) QoL, wellbeing (end scores) (sensitivity analysis) different scales for quality of life (QoL) · women in the peri‐ or postmenopausal phase Dehydroepiandrosterone for women in the peri‐ or postmenopausal phase (2015) · Cochrane | no estimate extracted | 8 studies · 287 participants | Moderate |
DHEA vs HT QoL, general wellbeing DHEA versus ET + P · Women in the peri‐ or postmenopausal phase Dehydroepiandrosterone for women in the peri‐ or postmenopausal phase (2015) · Cochrane | no estimate extracted | NR | No studies |
DHEA vs HT QoL, general wellbeing DHEA versus tibolone · Women in the peri‐ or postmenopausal phase Dehydroepiandrosterone for women in the peri‐ or postmenopausal phase (2015) · Cochrane | no estimate extracted | NR | No studies |
DHEA vs HT Acne DHEA versus ET · Women in the peri‐ or postmenopausal phase Dehydroepiandrosterone for women in the peri‐ or postmenopausal phase (2015) · Cochrane | OR 17 [0.9, 320.37] | 1 study · 50 participants | Very low |